Ovarian cancer (OC) is the seventh most common malignancy diagnosed among women,
the eighth leading cause of cancer mortality globally, and the most common cause of death …

Background Immune checkpoint inhibitors, including PD-L1 (programmed death ligand-1)
inhibitors have well documented anticancer therapeutic effect in most types of cancers but its …

Background: Patients with recurrent or persistent ovarian cancer often have poor prognoses,
and their optimal treatment regimen remains unclear. Inhibition of angiogenesis is a …

Simple Summary Ovarian cancer is one of the most aggressive tumors in the world due to its
clinical, biological, and molecular complexity. It is considered a “silent killer” due to the lack …

Clinical pregnancies and live births result from a complex interaction of molecular pathways
at the level of the female and male gametes during their development and interaction for …

This research aimed to probe the expression characteristics of poly (A)-binding protein
cytoplasmic 1 (PABPC1) and its role on the phenotype of ovarian cancer (OC) cells and to …

Introduction An estimated 20,000 women in the United States will receive a diagnosis of
ovarian cancer in 2023. Late-stage diagnosis is associated with poor prognosis. There is a …

Background As the development of novel anti-angiogenic drugs and the continuous
evolution of guideline recommendations, the efficacy and safety of anti-angiogenic agents in …

Simple Summary This study investigated a new drug, OPT-0139, an inhibitor of BRD4, a
protein involved in ovarian cancer. OPT-0139 treatment reduced the growth and viability of …

Breast cancer (BC) and ovarian cancer (OC) are among the most common and deadly
cancers affecting women worldwide. Both are complex diseases with marked heterogeneity …